CardioAktiv Taurine, tablets 500 mg 60 pcs

Pharmacotherapeutic group: metabolic agent.

ATC code: C01EB

Pharmacological properties

Pharmacodynamics

Taurine is a natural product of metabolism of sulfur-containing amino acids: cysteine, cysteamine, methionine. Taurine has osmoregulatory and membrane-protective properties, has a positive effect on the phospholipid composition of cell membranes, normalizes the exchange of calcium and potassium ions in cells.

Taurine shows properties of inhibitory neurotransmitter. It has anti-stressor effect and may regulate release of gamma-aminobutyric acid (GABA), adrenaline, prolactin and other hormones and regulate responses to them.

Involving in the synthesis of respiratory chain proteins in the mitochondria, taurine regulates oxidative processes and exhibits antioxidant properties and affects enzymes, such as cytochromes, involved in the metabolism of various xenobiotics.

Taurine improves metabolic processes in the heart, liver and other organs and tissues. In chronic diffuse liver disease taurine increases blood flow and reduces the severity of cytolysis.

The treatment with the preparation CardioAktiv® Taurine in case of cardiovascular failure (CVF) leads to the decrease of congestion in the small and large circulatory system: intracardiac diastolic pressure decreases, myocardial contractility increases (maximum contraction and relaxation rate, contractility and relaxation indices).

The drug moderately decreases blood pressure (BP) in patients with arterial hypertension and has almost no effect on BP in patients with cardiovascular insufficiency with reduced BP.

CardioAktiv^® Taurine reduces side effects from overdose of cardiac glycosides and slow calcium channel blockers; reduces hepatotoxicity of antifungal drugs. Improves performance under heavy physical exertion.

In diabetics, approximately 2 weeks after starting to take CardioActive^® Taurine reduces blood glucose concentrations. There is also a significant decrease in triglyceride concentration and, to a lesser extent, in cholesterol concentration, reduction of plasma atherogenicity of lipids. With long-term use of the drug (about 6 months) improvement of the microcirculatory blood flow in the eye was noted.

Pharmacokinetics

After a single oral administration of 500 mg of the preparation KardioAktiv^® Taurine, the active substance taurine is determined in blood in 15-20 minutes, reaching the maximum value in 1.5-2 hours. The drug is completely eliminated after 24 hours.

Indications

The drug is used in complex therapy:

cardiovascular failure of various etiologies;
intoxication caused by taking cardiac glycosides;
type 1 diabetes mellitus;
type 2 diabetes mellitus, including those with moderate hypercholesterolemia.

Pharmacological effect

Pharmacotherapeutic group: metabolic agent.

ATX code: C01EB

Pharmacological properties

Pharmacodynamics

Taurine is a natural metabolic product of sulfur-containing amino acids: cysteine, cysteamine, methionine. Taurine has osmoregulatory and membrane protective properties, has a positive effect on the phospholipid composition of cell membranes, and normalizes the exchange of calcium and potassium ions in cells.

Taurine has been shown to have the properties of an inhibitory neurotransmitter; it has an anti-stress effect, can regulate the release of gamma-aminobutyric acid (GABA), adrenaline, prolactin and other hormones, as well as regulate responses to them.

By participating in the synthesis of respiratory chain proteins in mitochondria, taurine regulates oxidative processes and exhibits antioxidant properties; affects enzymes such as cytochromes involved in the metabolism of various xenobiotics.

Taurine improves metabolic processes in the heart, liver and other organs and tissues. In chronic diffuse liver diseases, taurine increases blood flow and reduces the severity of cytolysis.

Treatment with CardioActiv® Taurine for cardiovascular failure (CVF) leads to a decrease in congestion in the pulmonary and systemic circulation: intracardiac diastolic pressure decreases, myocardial contractility increases (maximum rate of contraction and relaxation, contractility and relaxation indices).

The drug moderately reduces blood pressure (BP) in patients with arterial hypertension and has virtually no effect on blood pressure in patients with cardiovascular failure with low blood pressure.

CardioActiv® Taurine reduces side effects that occur with an overdose of cardiac glycosides and blockers of “slow” calcium channels; reduces the hepatotoxicity of antifungal drugs. Increases performance during heavy physical activity.

In case of diabetes mellitus, approximately 2 weeks after starting to take CardioActiv® Taurine, the concentration of glucose in the blood decreases. A significant decrease in the concentration of triglycerides was also noted, and to a lesser extent in the concentration of cholesterol, and a decrease in the atherogenicity of plasma lipids. With long-term use of the drug (about 6 months), an improvement in the microcirculatory blood flow of the eye was noted.

Pharmacokinetics

After a single oral dose of 500 mg of CardioActiv® Taurine, the active substance taurine is determined in the blood after 15-20 minutes, reaching a maximum after 1.5-2 hours. The drug is completely eliminated within a day.

Special instructions

Use with caution in patients with severely impaired renal function, when used simultaneously with cardiac glycosides, blockers of “slow” calcium channels (SCBC).

Active ingredient

Taurine

Composition

Composition per tablet

Active ingredient: taurine – 500 mg.

Auxiliary components:

povidone – 57.0 mg,

microcrystalline cellulose – 18.0 mg,

croscarmellose sodium – 17.2 mg,

calcium stearate – 4.8 mg,

colloidal silicon dioxide – 3.0 mg.

Pregnancy

The use of CardioActiv® Taurine during pregnancy and breastfeeding is not recommended due to the lack of sufficient experience in clinical use in this category of patients.

Contraindications

Severe heart failure in the decompensation stage.

Hypersensitivity to the drug.

CardioActive Taurine is not recommended for use in children under 18 years of age due to insufficient data on efficacy and safety.

Side Effects

Allergic reactions to the components of the drug are possible.

Interaction

CardioActive Taurine can be used with other medications.

Taurine enhances the inotropic effect of cardiac glycosides.

Overdose

There are no data on overdose.

Storage conditions

Store at a temperature not exceeding 25°C.

Shelf life

3 years.

Manufacturer

Evalar CJSC, Russia